Ocugen, Inc. · NASDAQ:OCGN

Ocugen — Q3 2021 Earnings Presentation

10 slides from Ocugen's earnings presentation, Nov 9, 2021

  1. Slide 1: Q3 2021 Financial Results and Business Update

    Q3 2021 Financial Results and Business Update NASDAQ: OCGN 1

  2. Slide 2: Forward Looking Statement

    2 Forward Looking Statement This presentation contains forward‐looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “conti

  3. Slide 3: Q3 2021 Financial Results and Business Update

    Q3 2021 Financial Results and Business Update NASDAQ: OCGN 3

  4. Slide 4: Forward Momentum for COVAXIN (BBV152)

    Forward Momentum for COVAXIN™ (BBV152) 4 01 02 WHO grants COVAXIN™ Emergency Use Listing, broadening global portfolio of COVID‐19 options Emergency Use Authorization submitted to FDA for pediatric (2‐ 18) indication for the prevention of COVID‐19 Investigational New Drug (IND) application filed with

  5. Slide 5: IND to evaluate COVAXIN (BBV152) among U.S. participants

    Investigational New Drug application (IND) to evaluate COVAXIN™ (BBV152) among U.S. participants 5 Development phase: 3 Number of subjects: A few hundred participants Primary objective: Demonstrate immuno‐bridging comparing US based participants following second dose of BBV152 to those who received

  6. Slide 6: Forward Momentum for Ocular Portfolio

    Forward Momentum for Ocular Portfolio 6 • Submitted IND for the treatment of retinitis pigmentosa resulting from genetic mutations, NR2E3 and RHO • Currently executing IND‐enabling preclinical studies to support a Phase 1 clinical trial OCU200 OCU40001 03 • Preclinical data shows OCU410 plays role i

  7. Slide 7: Financial Update

    FINANCIAL UPDATE © ocugen. C7]

  8. Slide 8: Financial Update: Statement of Operations and Balance Sheet Data

    Financial Update Statement of Operations Three months ended September 30, 2021 September 30, 2020 Research and development expense $(6.3) $(1.5) In‐process research and development expense ─ (7.0) General and administrative expense (4.5) (1.7) Other income (expense), net ─ (0.3) Net loss $(10.8) $(1

  9. Slide 9: Q&A

    9 Q&A

  10. Slide 10: Q3 2021 Financial Results and Business Update

    Q3 2021 Financial Results and Business Update NASDAQ: OCGN 10

Ocugen — Q3 2021 Earnings Presentation on 6ix